These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33296098)

  • 41. Increased expression of miR-552 acts as a potential predictor biomarker for poor prognosis of colorectal cancer.
    Wang N; Liu W
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):412-416. PubMed ID: 29424898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. miR-1260b is a Potential Prognostic Biomarker in Colorectal Cancer.
    Liu DR; Guan QL; Gao MT; Jiang L; Kang HX
    Med Sci Monit; 2016 Jul; 22():2417-23. PubMed ID: 27399918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The BRAF mutation is associated with the prognosis in colorectal cancer.
    Ahn TS; Jeong D; Son MW; Jung H; Park S; Kim H; Bae SB; Kim HJ; Jeon YW; Lee MS; Baek MJ
    J Cancer Res Clin Oncol; 2014 Nov; 140(11):1863-71. PubMed ID: 24942334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
    Sasaki Y; Hamaguchi T; Yamada Y; Takahashi N; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Nagai Y; Taniguchi H; Boku N; Ushijima T; Shimada Y
    Asian Pac J Cancer Prev; 2016; 17(2):539-43. PubMed ID: 26925640
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer.
    Yukimoto R; Nishida N; Hata T; Fujino S; Ogino T; Miyoshi N; Takahashi H; Uemura M; Satoh T; Hirofumi Y; Mizushima T; Doki Y; Eguchi H
    Cancer Sci; 2021 Jul; 112(7):2884-2894. PubMed ID: 33934428
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Jones JC; Renfro LA; Al-Shamsi HO; Schrock AB; Rankin A; Zhang BY; Kasi PM; Voss JS; Leal AD; Sun J; Ross J; Ali SM; Hubbard JM; Kipp BR; McWilliams RR; Kopetz S; Wolff RA; Grothey A
    J Clin Oncol; 2017 Aug; 35(23):2624-2630. PubMed ID: 28486044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.
    Toiyama Y; Hur K; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A
    Ann Surg; 2014 Apr; 259(4):735-43. PubMed ID: 23982750
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer.
    Yuan D; Li K; Zhu K; Yan R; Dang C
    Cancer Biol Ther; 2015; 16(2):268-75. PubMed ID: 25629978
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.
    Nakanishi R; Harada J; Tuul M; Zhao Y; Ando K; Saeki H; Oki E; Ohga T; Kitao H; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2013 Dec; 18(6):1042-8. PubMed ID: 23188063
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long noncoding RNA RP11-757G1.5 sponges miR-139-5p and upregulates YAP1 thereby promoting the proliferation and liver, spleen metastasis of colorectal cancer.
    Zhu X; Bu F; Tan T; Luo Q; Zhu J; Lin K; Huang J; Luo C; Zhu Z
    J Exp Clin Cancer Res; 2020 Oct; 39(1):207. PubMed ID: 33023613
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MicroRNA-466 (miR-466) functions as a tumor suppressor and prognostic factor in colorectal cancer (CRC).
    Tong F; Ying Y; Pan H; Zhao W; Li H; Zhan X
    Bosn J Basic Med Sci; 2018 Aug; 18(3):252-259. PubMed ID: 29338680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
    Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
    J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
    Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ
    Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer.
    Zhou T; Zhang G; Liu Z; Xia S; Tian H
    Int J Colorectal Dis; 2013 Jan; 28(1):19-24. PubMed ID: 22772712
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNA Expression in
    Lundberg IV; Wikberg ML; Ljuslinder I; Li X; Myte R; Zingmark C; Löfgren-Burström A; Edin S; Palmqvist R
    Anticancer Res; 2018 Feb; 38(2):677-683. PubMed ID: 29374690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway.
    Nosho K; Igarashi H; Nojima M; Ito M; Maruyama R; Yoshii S; Naito T; Sukawa Y; Mikami M; Sumioka W; Yamamoto E; Kurokawa S; Adachi Y; Takahashi H; Okuda H; Kusumi T; Hosokawa M; Fujita M; Hasegawa T; Okita K; Hirata K; Suzuki H; Yamamoto H; Shinomura Y
    Carcinogenesis; 2014 Apr; 35(4):776-83. PubMed ID: 24242331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.